Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis

Clinica Chimica Acta

Volumn 450, Issue , 2015, Pages 39-45

  Luo, Jian ^a   Wang, Ling Peng ^a   Hu, Hai Feng ^b   Zhang, Li ^a   Li, Ya Li ^a   Ai, Li Man ^a   Mu, Hu Yati ^a   Kun Wang, ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b Department of Internal Medicine ^*  (China)

Author keywords

All cause mortality; Cardiovascular mortality; Cystatin C; Meta analysis

Indexed keywords

CYSTATIN C;

ALL CAUSE MORTALITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ELDERLY CARE; GLOMERULUS FILTRATION RATE; HUMAN; MORTALITY; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; META ANALYSIS; RISK FACTOR;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CYSTATIN C; HUMANS; RISK FACTORS;

EID: 84938696026     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.07.016     Document Type: Review

References (39)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351:1296-1305.
2. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
3. Couser W.G., Remuzzi G., Mendis S., Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011, 80:1258-1270.
4. Stevens L.A., Coresh J., Greene T., Levey A.S. Assessing kidney function-measured and estimated glomerular filtration rate. N. Engl. J. Med. 2006, 354:2473-2483.
5. Mussap M., Plebani M. Biochemistry and clinical role of human cystatin C. Crit. Rev. Clin. Lab. Sci. 2004, 41:467-550.
6. Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 2002, 40:221-226.
7. Shlipak M.G., Sarnak M.J., Katz R., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N. Engl. J. Med. 2005, 352:2049-2060.
8. Shinkai S., Chaves P.H., Fujiwara Y., et al. Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch. Intern. Med. 2008, 168:200-206.
9. Deo R., Fyr C.L., Fried L.F., et al. Kidney dysfunction and fatal cardiovascular disease-an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am. Heart J. 2008, 155:62-68.
10. Zethelius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med. 2008, 358:2107-2116.
11. Lee M., Saver J.L., Huang W.H., Chow J., Chang K.H., Ovbiagele B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ. Cardiovasc. Qual. Outcomes 2010, 3:675-683.
12. Wu C.K., Lin J.W., Caffrey J.L., Chang M.H., Hwang J.J., Lin Y.S. Cystatin C and long-term mortality among subjects with normal creatinine-based estimated glomerular filtration rates: NHANES III (Third National Health and Nutrition Examination Survey). J. Am. Coll. Cardiol. 2010, 56:1930-1936.
13. Emberson J.R., Haynes R., Dasgupta T., et al. Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men. J. Intern. Med. 2010, 268:145-154.
14. Astor B.C., Shafi T., Hoogeveen R.C., et al. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am. J. Kidney Dis. 2012, 59:653-662.
15. Toft I., Solbu M., Kronborg J., et al. Cystatin C as risk factor for cardiovascular events and all-cause mortality in the general population. The Tromso Study. Nephrol. Dial. Transplant. 2012, 27:2780-2787.
16. Svensson-Farbom P., Ohlson Andersson M., Almgren P., et al. Cystatin C identifies cardiovascular risk better than creatinine-based estimates of glomerular filtration in middle-aged individuals without a history of cardiovascular disease. J. Intern. Med. 2014, 275:506-521.
17. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
18. Wells G., Shea B., O'Connell D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses (accessed May 6, 2015). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
19. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
20. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
21. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
22. Madero M., Sarnak M.J. Association of cystatin C with adverse outcomes. Curr. Opin. Nephrol. Hypertens. 2009, 18:258-263.
23. Coresh J., Byrd-Holt D., Astor B.C., et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J. Am. Soc. Nephrol. 2005, 16:180-188.
24. Mafham M., Emberson J., Landray M.J., Wen C.P., Baigent C. Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. PLoS One 2011, 6:e25920.
25. Zhang M., Cao X., Cai G., et al. Clinical evaluation of serum cystatin C and creatinine in patients with chronic kidney disease: a meta-analysis. J. Int. Med. Res. 2013, 41:944-955.
26. Zhang Z., Lu B., Sheng X., Jin N. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am. J. Kidney Dis. 2011, 58:356-365.
27. Feng Y., Zhang Y., Li G., Wang L. Relationship of cystatin-C change and the prevalence of death or dialysis need after acute kidney injury: a meta-analysis. Nephrology (Carlton) 2014, 19:679-684.
28. Pan P., Binjie H., Min L., et al. A meta-analysis on diagnostic value of serum cystatin C and creatinine for the evaluation of glomerular filtration function in renal transplant patients. Afr. Health Sci. 2014, 14:1025-1035.
29. Koenig W., Twardella D., Brenner H., Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin. Chem. 2005, 51:321-327.
30. Shlipak M.G., Katz R., Fried L.F., et al. Cystatin-C and mortality in elderly persons with heart failure. J. Am. Coll. Cardiol. 2005, 45:268-271.
31. Helmersson-Karlqvist J., Arnlov J., Carlsson A.C., Harma J., Larsson A. Increased urinary cystatin C indicated higher risk of cardiovascular death in a community cohort. Atherosclerosis 2014, 234:108-113.
32. Donahue R.P., Stranges S., Rejman K., Rafalson L.B., Dmochowski J., Trevisan M. Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care 2007, 30:1724-1729.
33. Kestenbaum B., Rudser K.D., de Boer I.H., et al. Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann. Intern. Med. 2008, 148:501-508.
34. Luc G., Bard J.M., Lesueur C., et al. Plasma cystatin-C and development of coronary heart disease: the PRIME Study. Atherosclerosis 2006, 185:375-380.
35. Moran A., Katz R., Smith N.L., et al. Cystatin C concentration as a predictor of systolic and diastolic heart failure. J. Card. Fail. 2008, 14:19-26.
36. Sarnak M.J., Katz R., Stehman-Breen C.O., et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann. Intern. Med. 2005, 142:497-505.
37. Ni L., Lu J., Hou L.B., et al. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 2007, 38:3287-3288.
38. O'Hare A.M., Newman A.B., Katz R., et al. Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch. Intern. Med. 2005, 165:2666-2670.
39. Fricker M., Wiesli P., Brandle M., Schwegler B., Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003, 63:1944-1947.